NanoRap Inc., located at the JHTV, Baltimore, MD is pioneering a novel therapeutic paradigm at the intersection of longevity science and metabolic health. By leveraging an established, clinically validated active pharmaceutical ingredient within a proprietary targeted delivery platform, we are developing high-precision therapies designed to treat the root cellular drivers of age-related decline and metabolic dysfunction.

Our approach integrates continuous, biomarker-guided surveillance to dynamically monitor immune response and metabolic activity, enabling a truly personalized medicine framework for both anti-aging and anti-obesity indications. Operating in a disciplined stealth posture, NanoRap is executing rigorous preclinical milestones to transform systemic therapeutic agents into targeted, patient-calibrated solutions.